Trevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Trevi Therapeutics said it has initiated FDA-aligned Phase III trials for its lead idiopathic pulmonary fibrosis (IPF) cough program. The single-asset biotech is also pursuing cough associated with other interstitial lung diseases and refractory chronic cough, with initial data expected later in 2026 and additional readouts in the second half of 2027. The clinical progress and defined regulatory path are constructive, though the investment case remains dependent on upcoming trial outcomes.

Analysis

TRVI should trade primarily as a binary development-duration asset rather than on near-term commercial fundamentals. Its valuation sensitivity will be dominated by the probability of a clinically meaningful and regulator-acceptable cough endpoint, with an additional discount for single-asset concentration and any financing required to bridge the full readout sequence. Management’s characterization of regulatory alignment is encouraging but not independently sufficient; the key diligence items are endpoint hierarchy, multiplicity control, placebo assumptions, discontinuation rates, and cash runway through the latest pivotal catalyst.

The competitive setup is more nuanced than a simple chronic-cough opportunity. P2X3 programs may validate the category but also establish efficacy, tolerability, and payer benchmarks; a differentiated safety or taste-disturbance profile could support TRVI’s positioning, while stronger-than-expected competitor data would raise the required efficacy bar. For IPF franchise owners BIIB/BI and Roche (RHHBY), an effective cough adjunct could improve persistence on antifibrotics indirectly, making them plausible future commercial partners rather than direct losers.

Near-term upside is likely catalyst-driven and vulnerable to dilution before pivotal data, especially if biotech risk appetite weakens. Over the next 6-18 months, positive data would justify a sharp probability-of-approval rerating; failure on a patient-reported endpoint, even with directional symptom improvement, could impair the entire platform because indication diversification does not equal asset diversification. Consensus may underappreciate that a successful IPF-cough study can de-risk regulatory measurement and enrollment execution for the broader chronic-cough program, creating a larger-than-linear read-through.

Key Decisions for Investors

• Maintain TRVI as a watch-list event trade until protocol-level endpoint details, enrollment progress, and cash runway are confirmed; do not underwrite management commentary as a probability-of-success increase without those data.
• For biotech-dedicated capital, initiate only a small 0.5-1.0% long TRVI position 3-6 months before the first pivotal readout, sized as a binary loss risk; add only if cash extends beyond the subsequent data event without materially dilutive financing.
• Use defined-risk upside exposure if listed options have adequate liquidity: buy calls or call spreads spanning the first readout rather than outright stock if implied volatility remains below modeled binary-event value; avoid structures that expire before data timing is firm.
• Falsify a constructive thesis on a material trial-timeline slip, guidance indicating financing before the next major data catalyst, or disclosure that primary endpoint/statistical assumptions differ from prior clinically meaningful cough-study precedents.
• Monitor GSK and other P2X3-category readouts as competitive benchmarks, not necessarily pair-trade shorts: superior efficacy with manageable tolerability would compress TRVI’s eventual commercial assumptions even before its own data.